Clinical trials: Lymphatic System Neoplasm
Lymphoblastic Leukemia, Acute, Childhood
Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol
The study will investigate, in children with acute lymphoblastic leukemia during maintenance treatment, if addition of allopurinol to conventional oral 6-mercaptopurine and methotrexate therapy, affects erythrocyte concentrations…
- Trial name
- NCT03022747
- Testing
- Allopurinol, Standard treatment
- Where
- 3 sites in Finland, Sweden
- Volunteers
- 60 people
- Sponsor
- Vastra Gotaland Region
Lymphoma, Hodgkin Lymphoma
The Pathogenesis and Prognostic Factors of Lymphoma
The aim of this study is to describe the clinical and genetic characteristics of Chinese lymphoma patients, and to explore the relationship between those characteristics and phatogenesis.
- Conditions
- Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
- Trial name
- NCT06203652
- Testing
- Real-world regimen
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Shanghai Zhongshan Hospital
Leukemia, Lymphocytic, Acute
Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT
B cell acute lymphoblastic leukemia (B-ALL)/Lymphoblastic lymphoma (LBL) is a hematological malignancy caused by malignant transformation and clonal expansion of B-lineage precursor cells.
- Trial name
- ZJU-HSCT-INO (NCT06861348)
- Testing
- Inotuzumab Ozogamicin±Donor Lymphocyte Infusion
- Where
- China
- Volunteers
- 23 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
B Cell Lymphoma, Acute Lymphoblastic Leukemia
Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of anti-CD22 CAR-T cells in patients with relapsed or refractory B-cell Malignancies.
- Trial name
- NCT04007978
- Testing
- Third generation CAR-T cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia (2015)
This study is a prospective multicenter observational study to evaluate the feasibility and the efficacy of the conditioning regimens which are modified by the donor differences and the age of recipients among patients who will…
- Trial name
- ATLAS2015 (NCT02428517)
- Testing
- AlloHCT for Young/MSD, AlloHCT for Young/MUD&FMD, AlloHCT for Old/MSD
- Where
- 4 sites in South Korea
- Volunteers
- 20 people
- Sponsor
- Asan Medical Center
Hodgkin Lymphoma
Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
This is an open-label, Phase 2/3，multicenter and single-arm clinical trial of Camrelizumab plus decitabine for Anti-PD-1 treatment-naive patients with relapsed or refractory Hodgkin Lymphoma.
- Trial name
- NCT04510610
- Testing
- Camrelizumab and Decitabine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Lymphoma
Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma
This single-arm, multicenter Phase 2 study will treat the patients who have Recurrent or refractory diffuse large B cell lymphoma with an infusion of the patient's own T cells that have been genetically modified to express a…
- Trial name
- EECBL (NCT02728882)
- Testing
- CD19-targeted CAR-T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sinobioway Cell Therapy Co., Ltd.
B-Cell Leukemia, Non-Hodgkin's Lymphoma
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
This is a phase I dose-finding trial of an autologous CD22 targeting chimeric antigen receptor (CAR)-T cell product, called CLIC-2201, for participants with relapsed/refractory B cell malignancies.
- Conditions
- B-Cell Leukemia, Non-Hodgkin's Lymphoma, B-cell Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT06208735
- Testing
- CLIC-2201
- Where
- 7 sites in Canada
- Volunteers
- 24 people
- Sponsor
- British Columbia Cancer Agency
Acute Myeloid Leukemia
MRD Response-adapted Allo-HSCT for Adverse-risk AML
This TROPHY-AML01 regimen aims to identify the effectiveness and safety of MRD response-adapted allo-HSCT for adverse-risk acute myeloid leukemia in an open-label, randomized, controlled trial.
- Trial name
- NCT06301425
- Testing
- Intervention group, Control group
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Peking University People's Hospital
Obesity, Childhood, Diabetes Mellitus, Type 2
The QUebec Adipose and Lifestyle InvesTigation in Youth (QUALITY) Cohort
The QUebec Adipose and Lifestyle InvesTigation in Youth (QUALITY) Cohort study is a unique and comprehensive longitudinal study of 630 Caucasian children and their parents that was designed to investigate the natural history and…
- Conditions
- Obesity, Childhood, Diabetes Mellitus, Type 2, Cardiovascular Risk Factor, Pediatric ALL
- Trial name
- QUALITY (NCT03356262)
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- St. Justine's Hospital
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT03630991
- Testing
- Edetate Calcium Disodium, Multivitamin, Succimer
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia, in Relapse
Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT
This is a single arm, open-label, multi-center, phase 1-2a study to determine the Maximum Tolerated Dose and/or the Recommended Phase 2 Dose and the safety of CARCIK-CD19 in adult and pediatric patients with relapsed or…
- Trial name
- CARCIK (NCT03389035)
- Testing
- CARCIK-CD19
- Where
- 2 sites in Italy
- Volunteers
- 21 people
- Sponsor
- Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Graft Versus Host Disease, Leukemia
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00608517
- Testing
- anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder
RATIONALE: Combining antithymocyte globulin with combination chemotherapy before donor peripheral stem cell transplantation may reduce the chance of developing graft-versus-host disease following transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00054340
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
This is a phase I study of temsirolimus (Torisel) combined with dexamethasone, cyclophosphamide and etoposide in patients with relapsed acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL) or peripheral T-cell lymphoma…
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
- Trial name
- NCT01614197
- Testing
- Temsirolimus, Etoposide, Cyclophosphamide
- Where
- 32 sites in United States, Australia and 1 more
- Volunteers
- 16 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Leukemia, Renal Toxicity
Kidney Dysfunction in Children and Young Adults Who Have Received Methotrexate for Acute Lymphoblastic Leukemia
RATIONALE: Gathering information about how often kidney dysfunction occurs in children and young adults receiving methotrexate for acute lymphoblastic leukemia may help doctors learn more about the disease and plan the best…
- Trial name
- NCT00993135
- Testing
- methotrexate, medical chart review, assessment of therapy complications
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Vanderbilt University Medical Center
Acute Lymphocytic Leukemia
Establishment of Acute Lymphocytic Leukemia Data Base in the Department of Oncology
Establishment of Acute Lymphocytic Leukemia Data Base in the Department of Oncology
- Trial name
- NCT01310946
- Testing
- Database
- Where
- Saudi Arabia
- Volunteers
- 203 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Acute T Cell Lymphoblastic Leukemia, Haploidentical Hematopoietic Stem Cell Transplantation
Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients
The goal of this clinical trial is to learn if haploidentical hematopoietic cell transplantation combined with an unrelated cord blood unit (haplo-cord HCT) works to treat acute T cell lymphoblastic leukemia (T-ALL).
- Conditions
- Acute T Cell Lymphoblastic Leukemia, Haploidentical Hematopoietic Stem Cell Transplantation, Cord Blood
- Trial name
- NCT06381817
- Testing
- Haplo-cord HCT, Haplo-HCT
- Where
- China
- Volunteers
- 146 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Melanoma, Ovarian Cancer
Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease
This protocol is to provide follow-up medical/surgical visits for DCS patients who are long term survivors and may not currently be a participant entered on an active research protocol.
- Conditions
- Melanoma, Ovarian Cancer, Prostate Cancer, Breast Cancer
- Trial name
- NCT00001503
- Where
- United States
- Volunteers
- 1,031 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkin Lymphoma
PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma
A prospective, multicenter, randomized controlled clinical study of camrelizumab in combination with ivarmacitinib as first-line treatment for pediatric classical Hodgkin lymphoma
- Trial name
- NCT07641010
- Testing
- PD-1+JAK1i, PD-1
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.